Business · 21/05/2018
FDA Announces Draft Guidance for Developing CMV Drugs for Transplant Patients
The FDA is releasing a draft guidance to help pharmaceutical companies develop medications to treat or prevent cytomegalovirus disease in patients who have undergone solid organ or hematopoietic stem cell transplants.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →